Protagonist Therapeutics (PTGX) Projected to Post Quarterly Earnings on Wednesday

Key Points

• Protagonist Therapeutics will report Q1 2026 results after the close on Wednesday, May 6, with analysts expecting EPS of ($0.65) and $12.205M in revenue; a conference call is scheduled for May 7 at 4:00 PM ET.
• In the prior quarter (reported Feb. 25) the company missed estimates, posting ($0.69) EPS versus ($0.53) expected and revenue of $7.44M versus $14.92M consensus, with a deeply negative net margin and negative return on equity.
• Shares trade near $101 with a market cap of $6.46B and a consensus rating of Moderate Buy (price target $108.15), while insiders have sold roughly 158,215 shares (~$15.54M) in the last 90 days.

Protagonist Therapeutics (NASDAQ:PTGX - Get Free Report) is expected to be issuing its Q1 2026 results after the market closes on Wednesday, May 6th. Analysts expect the company to announce earnings of ($0.65) per share and revenue of $12.2050 million for the quarter. Individuals can check the company's upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Thursday, May 7, 2026 at 4:00 PM ET.

Protagonist Therapeutics (NASDAQ:PTGX - Get Free Report) last issued its quarterly earnings data on Wednesday, February 25th. The company reported ($0.69) earnings per share for the quarter, missing the consensus estimate of ($0.53) by ($0.16). Protagonist Therapeutics had a negative return on equity of 19.89% and a negative net margin of 282.83%.The business had revenue of $7.44 million during the quarter, compared to analyst estimates of $14.92 million. On average, analysts expect Protagonist Therapeutics to post $1 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Protagonist Therapeutics Stock Up 2.7%

Shares of Protagonist Therapeutics stock opened at $101.21 on Wednesday. Protagonist Therapeutics has a twelve month low of $41.28 and a twelve month high of $107.84. The company has a 50-day simple moving average of $97.87 and a two-hundred day simple moving average of $88.62. The stock has a market capitalization of $6.46 billion, a price-to-earnings ratio of -49.37 and a beta of 2.12.

Analysts Set New Price Targets

Several analysts have weighed in on the stock. TD Cowen lifted their price objective on shares of Protagonist Therapeutics from $90.00 to $100.00 and gave the stock a "buy" rating in a research note on Thursday, February 26th. Leerink Partners lifted their price objective on shares of Protagonist Therapeutics from $107.00 to $110.00 and gave the stock an "outperform" rating in a research note on Thursday, March 19th. HC Wainwright lifted their price objective on shares of Protagonist Therapeutics from $80.00 to $117.00 and gave the stock a "buy" rating in a research note on Friday, January 30th. Johnson Rice reiterated a "buy" rating on shares of Protagonist Therapeutics in a research note on Wednesday, March 18th. Finally, Weiss Ratings cut shares of Protagonist Therapeutics from a "hold (c-)" rating to a "sell (d+)" rating in a research note on Tuesday, February 17th. Thirteen research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $108.15.

Insider Buying and Selling

In other news, Director William D. Waddill sold 20,000 shares of the business's stock in a transaction that occurred on Friday, February 6th. The shares were sold at an average price of $83.68, for a total value of $1,673,600.00. Following the completion of the transaction, the director directly owned 7,825 shares in the company, valued at approximately $654,796. The trade was a 71.88% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Harold E. Selick sold 24,000 shares of the business's stock in a transaction that occurred on Thursday, March 26th. The shares were sold at an average price of $105.00, for a total transaction of $2,520,000.00. Following the completion of the transaction, the director owned 60,845 shares of the company's stock, valued at $6,388,725. The trade was a 28.29% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 158,215 shares of company stock worth $15,539,786. 4.90% of the stock is owned by company insiders.

Hedge Funds Weigh In On Protagonist Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. Greenline Wealth Management LLC bought a new stake in shares of Protagonist Therapeutics during the 4th quarter valued at approximately $27,000. Truvestments Capital LLC grew its holdings in shares of Protagonist Therapeutics by 60.8% during the 4th quarter. Truvestments Capital LLC now owns 1,161 shares of the company's stock valued at $101,000 after purchasing an additional 439 shares during the last quarter. Osaic Holdings Inc. grew its holdings in shares of Protagonist Therapeutics by 79.5% during the 2nd quarter. Osaic Holdings Inc. now owns 1,185 shares of the company's stock valued at $65,000 after purchasing an additional 525 shares during the last quarter. Quadrant Capital Group LLC bought a new stake in shares of Protagonist Therapeutics during the 3rd quarter valued at approximately $90,000. Finally, Smartleaf Asset Management LLC grew its holdings in shares of Protagonist Therapeutics by 23.1% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,727 shares of the company's stock valued at $151,000 after purchasing an additional 324 shares during the last quarter. 98.63% of the stock is currently owned by institutional investors and hedge funds.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc NASDAQ: PTGX is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist's approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.

Among its lead programs is PTG-100, an oral α4β7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.